Xcout Intel
Centaurus Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Centaurus Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Centaurus Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Centaurus Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Centaurus Therapeutics, Inc.
Centaurus Therapeutics is a clinical-stage biotechnology company that develops first-in-class small-molecule therapies targeting ceramides to treat cardio-kidney-metabolic (CKM) diseases. The company's lead oral asset, CNT2130, inhibits DES1 to reduce excess ceramide production and restore lipid balance for patients suffering from organ decline.
Centaurus Therapeutics, Inc. at a glance
Centaurus Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $4M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $2M in June 2026. Xcout tracks 1 named person at Centaurus Therapeutics, Inc., including Dr Mike Westby (Chief Scientific Officer).
Centaurus Therapeutics, Inc. leadership
- Dr Mike WestbyChief Scientific Officer
Centaurus Therapeutics, Inc. funding rounds
At least $4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $2M | 7 named | |
| SEC Form D filing | $2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Centaurus Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Centaurus Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Grand Rapids, Michigan, focused on developing innovative therapies for metabolic and liver diseases.
Similar biotechnology company
Centessa Pharmaceuticals LLC is a biotechnology research company headquartered in Boston, Massachusetts, United States. The company comprises leaders, innovators, and scientists dedicated to pursuing and developing transformational medicines for patients.
Similar biotechnology company
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to revolutionizing oral therapies for obesity and metabolic diseases.
Biotech
Akero Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is dedicated to developing transformational therapies for metabolic dysfunction-associated steatohepatitis and other metabolic diseases.
Similar biotechnology company
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.
Biotech
89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for patients with liver and cardiometabolic diseases. The company utilizes its expertise in FGF21 as a master metabolic regulator to create treatments, such as pegozafermin, for conditions with limited or no approved therapeutic options.
Biotech
ENYO Pharma is a clinical-stage biopharmaceutical company that develops therapeutics for patients with impaired kidney function. Its lead compound, Vonafexor, is a small molecule currently in Phase 2 development to treat rare kidney diseases such as Alport syndrome and chronic kidney disease.
Similar biotechnology company
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Life Science
Gemphire Therapeutics was a U.S. clinical-stage biopharmaceutical company developing gemcabene, an investigational lipid-modulating drug intended to treat dyslipidemia and related cardiovascular and metabolic conditions. It served patients with difficult-to-treat lipid disorders, including severe hypertriglyceridemia and familial hypercholesterolemia.
Similar biotechnology company
Aro Biotherapeutics is a U.S. biotechnology company developing targeted therapeutics using its Centyrin protein platform, including delivery of genetic medicines to specific tissues and cells. It serves patients with serious diseases and partners or works with biopharmaceutical organizations to advance targeted drug-development programs.
Similar biotechnology company
Cadenza Bio, Inc. is a privately held preclinical biotechnology company founded in 2022 and headquartered in Oklahoma City, dedicated to developing novel, non-steroidal, highly selective small-molecule therapies.
Similar biotechnology company
Alesta Therapeutics is a clinical-stage biotechnology company based in Leiden, Netherlands, dedicated to developing novel oral small-molecule therapies targeting GCN2 for underserved rare diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Centaurus Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Centaurus Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →